Results 201 to 210 of about 101,312 (221)
Some of the next articles are maybe not open access.
Journal of Investigative Medicine
Combined administration of two or more drugs is emerging as a new strategy in triple-negative breast neoplasms. This is the first study to investigate the combination of the histone deacetylase inhibitor mocetinostat and the antimetabolite drug capecitabine in triple-negative mammary neoplasms in a preclinical mouse model.
Hacer Kaya Çakir, Onur Eroğlu
openaire +5 more sources
Combined administration of two or more drugs is emerging as a new strategy in triple-negative breast neoplasms. This is the first study to investigate the combination of the histone deacetylase inhibitor mocetinostat and the antimetabolite drug capecitabine in triple-negative mammary neoplasms in a preclinical mouse model.
Hacer Kaya Çakir, Onur Eroğlu
openaire +5 more sources
Learning objectives Background Findings and procedure details Conclusion Personal information and conflict of interest ...
openaire +1 more source
openaire +1 more source
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
Cancers, 2022Rola F Jaafar +2 more
exaly
Breast Cancer Statistics, 2022
Ca-A Cancer Journal for Clinicians, 2022, Kimberly Miller, Hyuna Sung
exaly
Pathogenesis of Triple-Negative Breast Cancer
Annual Review of Pathology: Mechanisms of Disease, 2022Fatemeh Derakhshan, Jorge Reis-Filho
exaly
Metabolic Reprogramming in Triple-Negative Breast Cancer
Frontiers in Oncology, 2020Jingyi Guo, Mozhi Wang, Yu Xueting
exaly
Breast cancer statistics, 2017, racial disparity in mortality by state
Ca-A Cancer Journal for Clinicians, 2017Ahmedin Jemal +2 more
exaly